Genevant sciences and arbutus biopharma initiate international patent infringement enforcement actions against moderna

Basel, switzerland and vancouver, b.c. and warminster, pa., march 03, 2025 (globe newswire) -- genevant sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (lnp) patent portfolio (a subsidiary of roivant sciences, ltd. (nasdaq: roiv)), and arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative lnp technology against moderna, inc. and certain affiliates. together, the enforcement actions target alleged infringing activities in 30 countries.
ABUS Ratings Summary
ABUS Quant Ranking